GLG News by Dr. Gary Barker, Partner and Co-Founder
GLG News is now G+ Insights
-
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
-
Welcome addition to our armament, but overuse potential?
July 14, 2009
Bausch and Lomb (BOL) Receives FDA Approval of Besivance(TM), New Topical Ophthalmic Antibacterial for the Treatment of Bacterial Conjunctivitis ('Pink Eye') | www.lifescience-online.com
Potential for overuse and more drug-resistant bacteria
-
Will J&J's new one-day lens effect the one-day market?
November 17, 2008
Johnson & Johnson Vision Care Announces First Daily Disposable Silicone Hydrogel at BCLA | www.cltoday.com
New innovations in the contact lens market are needed to boost growth in sales, especially in the one-day lens market.
-
Is LASIK the issue or is choosing the right refractive surgery for the right patient the real issue?
May 7, 2008
LASIK Worries? Some May See Better with Alternatives | www.washingtonpost.com
I welcome the FDA investigation of LASIK, as thousands of patients are undergoing the elective cosmetic procedure, with some achieving less than optimum results. Will the study show that LASIK is not safe, or will it show that LASIK is not the real issue, rather that patient selection is the true issue?
-
Injectable glaucoma drug vs. patient compliance
April 15, 2008
Injectable glaucoma drug shown to reduce IOP in clinical study | www.osnsupersite.com
Any new efficacious glaucoma treatment is welcome and needed, but patient compliance remains a factor. A single injection treatment that provides IOP reduction for 3 months would greatly improve success in IOP control. I would, however, like to see a lower target pressure set for the study.
-
April 15, 2008
Novartis to buy Nestle's Alcon stakes for $39 billion | www.wtnzfox43.com
The purchase of a controlling interest in Alcon by Novartis is a brilliant move by Novartis. To bring the leading contact lens disinfectant together with Ciba's contact lenses is a wonderful marketing opportunity for Ciba.
-
Neuroprotection is the Key in Glaucoma Treatment
October 7, 2007
Targeting amyloid- b in Glaucoma | www.pnas.org
To delve further into the reasons for retinal ganglion cell death is critical for the future of glaucoma treatment. As the article discusses, there are reasons for retinal ganglion cell death other than high intraocular pressures. Unfortunately, the only medical and surgical methods we have to treat glaucoma are to simply lower the intraocular pressure. Better, more effective treatments are needed.
-
Bifocal Contact Lenses-Have They Finally Achieved Success?
March 27, 2007
Better Vision Without Looking Your Age | www.nytimes.com
The market for high-performing soft bifocal lenses is huge, and will continue to grow as the Baby Boomers age and their disposable income grows.
-
Ceragenin-based Contact Lens Disinfectant Solution--Is it Really a Better Mousetrap?
March 27, 2007
Contact lens disinfectant proves effective in early tests | www.osnsupersite.com
A possibly more effective contact lens disinfectant that what is currently available, but can it compete in real world trials.
Page : 11 to 8 of 8
- Subscribe to Updates
-
Leading institutions connect with Gary Barker through GLG
Most Popular Healthcare News
-
February 7, 2012
-
What do the cloud, collaboration and virtualization have in common?
January 27, 2012
-
Clinical diagnostic acquisitions dominate 2011 top ten list
January 12, 2012
-
Gene therapy success threatens drugs for hemophilia and rare diseases
December 13, 2011
-
Medtech M&A activity accelerates in 2011
November 30, 2011
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.